title: [Cutaneous side effects of EGF receptor inhibitors].
abstract: EGFR receptor inhibitors are used for the treatment of a number of solid tumors. Their cutaneous toxicity is a specific and frequent side effect that has shown to be correlated to the antitumoral effect. Here, we present an overview of the cutaneous manifestations and management of EGF receptor inhibitors toxicity.
authors.affiliation: Hôpital Tenon, Service de dermatologie-allergologie, 4, rue de la Chine, 75020 Paris, France. dany.nassar@inserm.fr
authors.forename: D
authors.initials: D
authors.lastname: Nassar
authors.forename: B
authors.initials: B
authors.lastname: Soutou
authors.forename: S
authors.initials: S
authors.lastname: Aractingi
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005499:Folliculitis / Q000139:chemically induced* / Q000473:pathology / Q000628:therapy; D000077156:Gefitinib; D006801:Humans; D009260:Nail Diseases / Q000139:chemically induced; D000077544:Panitumumab; D011799:Quinazolines / Q000009:adverse effects; D012867:Skin / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011799:Quinazolines; D000077544:Panitumumab; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000068818:Cetuximab; D000077156:Gefitinib